Indeed, while the levels of CHI3L1 and CHI3L2 in AD patients tend to increase leading to hypothesis of a potential immunological role, CHID1 levels tend to decrease both with age and in neurological diseases such as AD. This evidence concerns the gene CHI3L2 and nervous system disorder.